Correlation Between Reviva Pharmaceuticals and Puma Biotechnology

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Reviva Pharmaceuticals and Puma Biotechnology at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Reviva Pharmaceuticals and Puma Biotechnology into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Reviva Pharmaceuticals Holdings and Puma Biotechnology, you can compare the effects of market volatilities on Reviva Pharmaceuticals and Puma Biotechnology and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Reviva Pharmaceuticals with a short position of Puma Biotechnology. Check out your portfolio center. Please also check ongoing floating volatility patterns of Reviva Pharmaceuticals and Puma Biotechnology.

Diversification Opportunities for Reviva Pharmaceuticals and Puma Biotechnology

0.04
  Correlation Coefficient

Significant diversification

The 3 months correlation between Reviva and Puma is 0.04. Overlapping area represents the amount of risk that can be diversified away by holding Reviva Pharmaceuticals Holding and Puma Biotechnology in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Puma Biotechnology and Reviva Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Reviva Pharmaceuticals Holdings are associated (or correlated) with Puma Biotechnology. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Puma Biotechnology has no effect on the direction of Reviva Pharmaceuticals i.e., Reviva Pharmaceuticals and Puma Biotechnology go up and down completely randomly.

Pair Corralation between Reviva Pharmaceuticals and Puma Biotechnology

Given the investment horizon of 90 days Reviva Pharmaceuticals Holdings is expected to generate 1.88 times more return on investment than Puma Biotechnology. However, Reviva Pharmaceuticals is 1.88 times more volatile than Puma Biotechnology. It trades about 0.19 of its potential returns per unit of risk. Puma Biotechnology is currently generating about 0.07 per unit of risk. If you would invest  117.00  in Reviva Pharmaceuticals Holdings on September 16, 2024 and sell it today you would earn a total of  144.00  from holding Reviva Pharmaceuticals Holdings or generate 123.08% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Reviva Pharmaceuticals Holding  vs.  Puma Biotechnology

 Performance 
       Timeline  
Reviva Pharmaceuticals 

Risk-Adjusted Performance

14 of 100

 
Weak
 
Strong
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Reviva Pharmaceuticals Holdings are ranked lower than 14 (%) of all global equities and portfolios over the last 90 days. Despite fairly inconsistent basic indicators, Reviva Pharmaceuticals demonstrated solid returns over the last few months and may actually be approaching a breakup point.
Puma Biotechnology 

Risk-Adjusted Performance

5 of 100

 
Weak
 
Strong
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in Puma Biotechnology are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. Despite fairly unsteady basic indicators, Puma Biotechnology demonstrated solid returns over the last few months and may actually be approaching a breakup point.

Reviva Pharmaceuticals and Puma Biotechnology Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Reviva Pharmaceuticals and Puma Biotechnology

The main advantage of trading using opposite Reviva Pharmaceuticals and Puma Biotechnology positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Reviva Pharmaceuticals position performs unexpectedly, Puma Biotechnology can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Puma Biotechnology will offset losses from the drop in Puma Biotechnology's long position.
The idea behind Reviva Pharmaceuticals Holdings and Puma Biotechnology pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.

Other Complementary Tools

Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Technical Analysis
Check basic technical indicators and analysis based on most latest market data